You might have heard that COVID-19 vaccine trials are underway in Seattle. What exactly is being tested? How much longer will these tests take? And when can we expect a vaccine against the novel coronavirus? We chat with Benjamin Neuman, Ph.D., one of the world’s experts on coronavirus, and Daniel Wrapp, one of the scientists who mapped the structure of the protein that the coronavirus uses to infect your cells, to help us answer these questions
- Sources:
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- A Fusion Peptide in the Spike Protein of MERS Coronavirus
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- NIH Scientists Identify Atomic Structure of Novel Coronavirus Protein
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV.
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- How SARS hijacks host cells
- Mechanisms of viral assembly
- Timely development of vaccines against SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus Nonstructural Proteins 3, 4, and 6 Induce Double-Membrane Vesicles
- Scientists figure out how new coronavirus breaks into human cells
- A Spotlight on Viruses—Application of Click Chemistry to Visualize Virus-Cell Interactions
- How Viruses Invade Cells
- The proximal origin of SARS-CoV-2
- Thousands of scientists are racing to find a vaccine for coronavirus. 41 possibilities are in the works
- Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
- New coronavirus stable for hours on surfaces
- Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents
- Vaccines and Antiviral Drugs in Pandemic Preparedness
- On the binding affinity of macromolecular interactions: daring to ask why proteins interact
- Coronavirus envelope protein: current knowledge
- First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA
- The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?
;void(0);){kind=link}